Sentences with phrase «median survival»

Patients have a very poor prognosis, with median survival of just 14 to 16 months.

Several studies have shown median survival to be more than 6 months.

Some patients given both treatments lived significantly longer (years) than expected, while the overall median survival increased by 59 % (2.6 months).

Those that received the vaccine lived more than twice as long as the historical, matched, control group, with median survival times of 956 days compared to 423 days.

Glioblastma multiforme (GBM) is one of the most lethal primary brain tumors, with median survival for these patients only slightly over one year.

«Prior to this, the longest reported median survival time of dogs with hemangiosarcoma of the spleen that underwent no further treatment was 86 days.

«We increased median survival time in animals by 40 %, which gives us enough evidence to go on to human clinical trials,» Belcher says.

Dogs in the standard - dose and low - dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P < 0.001).

BRAF inhibitors prolonged median survival in clinical trials by about seven months.

Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician - in - Chief who devised the clinical trial, agreed: «Although a small study, the high response rate and landmark evolving median survival are very encouraging, and this regimen is being expanded for patients with stage IV pancreatic cancer.»

In fact, ipilimumab proved to be the first medication to significantly expand median survival rates in patients with advanced melanoma — from six months to 11.

These tumors are similar to glioblastoma, with patients» median survival at 18 months.

Although researchers found that delivering the Isis drug directly into the brain nearly doubled survival time in a mouse model of SMA3, systemic administration in the rodents — which usually die within two weeks — has been shown to extend median survival by up to eight months.

In the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated.

This cluster was composed mainly of oligodendrogliomas (84 percent) and had median survival of about eight years.

Median survival time for all dogs was 136 days (mean 179 + / -18 days).

Prognosis for dogs with pituitary - dependent Cushing's treated medically is good with a reported median survival rate of 2 years.

Reported median survivals for brain tumors treated with radiation vary.

This is particularly notable because metastatic pancreatic cancer is one of the deadliest forms of cancer, and life expectancy following diagnosis is very short, with median survival about 6 to 11 months.

While dogs receiving the highest dosage, 100 mg / kg / day, had the longest median survival time, it was noted that the difference in survival times between dosages was not statistically significant.

Without resection, overall median survival is four to six months with an estimated five - year survival rate of 0.4 percent to 5 percent.

Despite a possible improvement in median survival of RCC patients treated with VEGF or VEGF - R targeting agents, long - term survivors (> 5 years) are rare.

More specifically, their median survival is 9.6 years (compared to 6.4 years for the mouse lemurs in the control group).

Additionally, the median survival rate for patients who received radiosurgery was 440 days, compared to 202 days for patients who received whole - brain radiation.

The infection is virtually always fatal, with a median survival time after the onset of symptoms of four days.

DIPG affects a few hundred school - age children across the country each year and has a median survival time of only 10 months; there is no cure.

Despite current treatment strategies, the median survival for patients with the most aggressive brain cancer — called glioblastoma, is 15 months.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

Glioblastoma multiforme is the most common and aggressive form of brain cancer, with a median survival of about 15 months.

Of the dogs stricken with osteosarcoma, 35 had the cancer in a leg which was subsequently amputated, followed by chemotherapy, which is the standard - of - care treatment; the dogs with elevated total cholesterol had a median survival time of 455 days, more than 200 days greater than the median survival time for dogs with normal cholesterol.

In examining the STS - CMS linked data, researchers found that the median survival following lung cancer surgery for pathologic Stage I (early stage) was 6.7 years, almost 2 years longer than the benchmark 5 - year survival rate.

The median survival period for patients receiving TAS - 102 was 7.1 months, compared to 5.3 months for patients taking a placebo, investigators reported.

Median survival after RT was 3.5 months and 17.6 months following CLL progression, the results indicate.

The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years.

With standard treatments of surgery, chemotherapy and radiation, the median survival time is only 14.6 months, and improvement will only come with the ability to kill tumor cells resistant to standard treatments, according to Alfredo Quiñones - Hinojosa, M.D., a professor of neurosurgery at the Johns Hopkins University School of Medicine and a member of the research team.

The median survival rate for patients with metastatic uveal melanoma is 12 months.

Study results show that patients with prior knowledge of MGUS had better overall survival (median 2.8 years) than patients with MM who didn't know when they had MGUS (median survival 2.1 years), although patients with prior knowledge of their MGUS status had more coexisting illnesses.

In patients with HLA - A2 and methylated MGMT, neither the control group nor the treatment group has reached a median survival point to date.

Median survival for newly diagnosed GBM patients is only 14.6 months.

The therapy has greatly helped the majority of the patients, most of whom had undergone heavy treatments before and had prognoses with a median survival time (without the TAT therapy) of 2 - 4 months.

No dominant histology or grade type, median survival of about seven years.

Swayze managed to battle his cancer for 20 months, 12 more than the median survival time.

Despite recent advances in understanding this disease, the median survival of glioblastoma patients is only 15 months, and survival statistics have not significantly improved over the past three decades.

The researchers then tested their scoring method using data on 688 AML patients in three different clinical trials, In each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scores.

Researchers developed a new clinical approach to increase the efficiency of treatment that increased the median survival to 22 months — bringing much needed hope to those affected by this aggressive disease.

Patients diagnosed with this type of cancer, and who undergo current standard treatment, have a median survival of 16 months.

Based on recent information on the mechanisms of chemotherapy, a team of researchers of the McGill University Health Centre (MUHC) developed a new clinical approach to increase the efficiency of treatment in glioblastomas that increased the median survival to 22 months — bringing much needed hope to those affected by this aggressive disease.